// App-Quantinova.ai

e14095 : Relation of the BIM deletion polymorphism to intrinsic EGFR-TKI resistance of Chinese patients with EGFR mutant advanced non-small cell lung cancer.

Researchers

Presenter

  • Shuang Xin

Principal Investigators

  • Yuan Yuan Zhao

  • Yuxiang Ma

  • Xueding Wang

  • Yan Huang

  • Hongyun Zhao

  • Chen Zhu

  • Yunpeng Yang

  • Li Zhang

  • Min Huang

Medical Centers

  • Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

  • State Key Laboratory of Oncology in South China, Caner Center, Sun Yat-sen University, Guangzhou, China

  • Institution of Clinical Pharmacology, SUN-Yat Sen University, Guangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • BCL2 like 11

Drug/Treatment

  • Erlotinib hydrochloride

  • gefitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved